Drug intelligence / Profile preview

VAR 300

Development stage: Preclinical
Lead developer: Variant Pharmaceuticals
Administration: Intramuscular, Subcutaneous

Overview

VAR 300 is a drug candidate developed by Variant Pharmaceuticals, forming part of its renal pipeline. Incon, a South Korean technology company, has secured a period of exclusivity to negotiate commercial rights for VAR 300 in certain Asian countries, excluding Japan and Australia. The specific mechanism of action and primary indication for VAR 300 are not detailed in the provided context, though it is associated with renal diseases.

Beyond the preview

Go deeper on VAR 300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VAR 300.

Explore the full profile